HONG KONG – Increasingly concerned that the unchecked use of antibiotics is rapidly creating widespread resistance, regulators in Asia are developing stronger regulations and controls. Read More
HONG KONG – Stepped up regulations and a curb on the use of antibiotics is hurting the bottom line of antibiotic makers in China. And there is little chance of a change any time soon. Read More
Armed with a $44 million series B, Annexon Biosciences Inc. extended the development runway for its still-preclinical lead asset through completion of phase II programs designed to answer key questions about its pursuit of classical complement pathway inhibitors to treat neurodegenerative disorders. Read More
"Are there too many [immuno-oncology programs]? People with cancer are dying every day – we have a lot of work to do," Incyte Corp. CEO Hervé Hoppenot told BioWorld Today as his firm kicked off Echo-301, a phase III trial testing the oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor epacadostat in combination with Merck & Co. Inc.'s approved anti-PD-1 drug Keytruda (pembrolizumab) as first-line treatment for patients with advanced or metastatic melanoma. Read More
When it comes to finding a way to prevent or slow the progression of Alzheimer's disease, the question isn't "Are we there yet?" Rather, it's "Are we on the way?" Ronald Petersen, director of the Mayo Alzheimer's Disease Research Center, said at a policy discussion Thursday to launch the Alzheimer's Readiness Project. Read More
Structural studies published this week indicated there are antigens that would make it feasible to create a broad-spectrum vaccine that would simultaneously protect against both Zika and dengue virus. Read More
The annual report on the state of Medicare and Social Security is out, and the news for Medicare is not particularly bad for the short term, despite that the projected Part A trust fund depletion date has moved forward two years from last year's projection. Read More
Hengrui Therapeutics Inc. (HTI), of Princeton, N.J., said it inked an agreement with Bio Holdings Ltd., a joint venture between China's Jiangsu Hengrui's Medicine Co. Ltd. and an undisclosed blue chip investment firm, regarding a $100 million investment in HTI. Proceeds will be used to advance clinical trials. HTI is a recently formed startup with a pipeline of clinical-stage oncology and immuno-oncology assets. Read More
Alligator Bioscience AB, of Lund, Sweden, has contracted with Södertälje, Sweden-based Cobra Biologics, asking it to develop a second cell line for production of Alligator's new drug candidate ADC-1015, a bispecific immune activator. Terms were not disclosed. Read More
Redhill Biopharma Ltd., of Tel Aviv, Israel, said the first patients were dosed in a phase II study with Bekinda 12 mg for diarrhea-predominant irritable bowel syndrome. Read More
